Open AccessDeep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients
Author(s) -
Luke C. Swenson,
Tingting Mo,
Winnie Dong,
Xiaolin Zhong,
Conan K. Woods,
Mark A. Jensen,
A Thielen,
Doug Chapman,
Marilyn Lewis,
Ian James,
Jayvant Heera,
Hernán Valdez,
P. Richard Harrigan
Publication year - 2010
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiq030
Subject(s) - maraviroc , ccr5 receptor antagonist , v3 loop , medicine , placebo , tropism , virology , human immunodeficiency virus (hiv) , clinical trial , lentivirus , tissue tropism , immunology , virus , viral disease , receptor , pathology , chemokine receptor , alternative medicine , epitope , chemokine , antigen
The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) studies compared maraviroc versus placebo in treatment-experienced patients with CCR5-using (R5) human immunodeficiency virus type 1 (HIV-1), screened using the original Trofile assay. A subset with non-R5 HIV infection entered the A4001029 trial. We retrospectively examined the performance of a genotypic tropism assay based on deep sequencing of the HIV env V3 loop in predicting virologic response to maraviroc in these trials.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom